drugset / Trial / NCT00626522

Aclidinium/Formoterol Fixed Combination Dose Finding Study

NCT00626522

Phase 2 Completed 808 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

The study seeks to determine the optimal dose of the Aclidinium/Formoterol combination for investigation in Phase III clinical trials

Timeline

Start
2008-02
Primary completion
2008-11
Completion
2008-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Aclidinium Small molecule Inhaled
Subject Formoterol Other / unclassified Inhaled